Commonwealth Equity Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$985K Buy
320,991
+235,648
+276% +$911K ﹤0.01% 2631
2025
Q4
$349K Buy
85,343
+39,303
+85% +$195K ﹤0.01% 3523
2025
Q3
$225K Sell
46,040
-13,581
-23% -$71.3K ﹤0.01% 3866
2025
Q2
$302K Sell
59,621
-6,722
-10% -$33K ﹤0.01% 3574
2025
Q1
$351K Buy
66,343
+12,024
+22% +$87.7K ﹤0.01% 3350
2024
Q4
$367K Sell
54,319
-4,582
-8% -$30.8K ﹤0.01% 3231
2024
Q3
$388K Buy
58,901
+14,660
+33% +$105K ﹤0.01% 3115
2024
Q2
$332K Buy
44,241
+9,058
+26% +$79K ﹤0.01% 3212
2024
Q1
$351K Buy
35,183
+13,183
+60% +$147K ﹤0.01% 3131
2023
Q4
$217K Buy
22,000
+815
+4% +$5.81K ﹤0.01% 3445
2023
Q3
$162K Buy
21,185
+5,550
+35% +$55.4K ﹤0.01% 3460
2023
Q2
$117K Buy
+15,635
New +$109K ﹤0.01% 3547

Other funds holding RXRX